risk of compounded semaglutide Patient Safety Updates The FDA Warns of the

Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M

It is the combination of Glimepiride and Metformin

Patients with MASLD who have not yet developed cirrhosis represent an important population for observational studies to investigate the associations of GLP-1RAs. To determine whether use of GLP-1RAs is associated with lower incidence of cirrhosis and its complications in this patient population, Kanwal and colleagues conducted a retrospective study, using the national Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry

Their mechanism involves enhanced insulin release, delayed gastric emptying through reduced antral and duodenal motility with increased pyloric tone, and appetite suppression mediated via central nervous system pathways [4]

For cardiovascular health Both drugs are expected to show cardiovascular benefit based on their metabolic effects

Some important measurements of heart health showed noticeable improvements: Lower A1C Lower blood pressure Lower inflammation Lower total cholesterol, LDL-C, and triglycerides Lower weight GLP-1s have also proven to be effective in helping reduce cholesterol plaques associated with atherosclerosis and improving several factors in kidney function that affect the heart